Cancer immunotherapy may weaken bones, new study warns
NCT ID NCT07555210
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study looks at how immunotherapy drugs (anti-PD-1) affect bone strength in people being treated for cancer. Researchers will measure bone density and blood markers over a year in 25 patients. The goal is to understand if these treatments increase fracture risk, so doctors can better monitor and protect bone health.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for BREAST CANCER (TRIPLE NEGATIVE BREAST CANCER (TNBC)) are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Vanderbilt-Ingram Cancer Center
RECRUITINGNashville, Tennessee, 37232, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a Chest-Injected drug drain Cancer's fluid trap?
- Can a radioactive tracer reveal whether immunotherapy is working?
- Can a new nucleotide analogue boost cancer treatment?
- Can a pill that blocks multiple cancer proteins shrink Hard-to-Treat tumors?
- Can a Two-Pronged attack shrink Hard-to-Treat cancers?
- Can standard cancer treatment wake up the immune system? a study investigates.